Following doxorubicin-induced tumour cell death, C3 activation was also shown to modulate anti-tumour immune responses through inducing the recruitment of ICOSL expressing B-cells via the CR2 receptor expressed on B-cells. This evidence concerns the gene ICOSLG and neoplasm.